# Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients

Study · id `cardio:ct-nct01395823` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01395823](<https://clinicaltrials.gov/study/NCT01395823>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01395823

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 470 participants.

## Technical summary

Registry record NCT01395823. Randomized; quadruple masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2016-03-14.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 470 participants (enrolled count; ClinicalTrials.gov record NCT01395823, source copy `cardio:ctgov-nct01395823-2016-03-14`, retrieved 2026-10-26)
- Start date: 2011-06 (registry gives no type) (ClinicalTrials.gov record NCT01395823, source copy `cardio:ctgov-nct01395823-2016-03-14`, retrieved 2026-10-26)
- Primary completion: 2014-04 (actual) (ClinicalTrials.gov record NCT01395823, source copy `cardio:ctgov-nct01395823-2016-03-14`, retrieved 2026-10-26)
- Completion: 2015-06 (actual) (ClinicalTrials.gov record NCT01395823, source copy `cardio:ctgov-nct01395823-2016-03-14`, retrieved 2026-10-26)
- Results first posted: 2016-03-14 (ClinicalTrials.gov record NCT01395823, source copy `cardio:ctgov-nct01395823-2016-03-14`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01395823, source copy `cardio:ctgov-nct01395823-2016-03-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01395823-2016-03-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
- Condition: End Stage Renal Disease
- Intervention (Dietary supplement): ergocalciferol supplementation
- Intervention (Other): placebo
- Lead sponsor: Dialysis Clinic, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 0c143b7704deb8d242491208c11fd78064667bdb7c2e8875f9402027db52d86e
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
